Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Mar;72(3):388-96.
doi: 10.4088/JCP.09m05885blu.

Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample

Benedetto Vitiello  1 , Graham Emslie, Gregory Clarke, Karen Dineen Wagner, Joan R Asarnow, Martin B Keller, Boris Birmaher, Neal D Ryan, Betsy Kennard, Taryn L Mayes, Lynn DeBar, Frances Lynch, John Dickerson, Michael Strober, Robert Suddath, James T McCracken, Anthony Spirito, Matthew Onorato, Jamie Zelazny, Giovanna Porta, Satish Iyengar, David A Brent
Affiliations
Randomized Controlled Trial

Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample

Benedetto Vitiello et al. J Clin Psychiatry. 2011 Mar.

Erratum in

  • Correction.
    Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes TL, DeBar L, Lynch F, Dickerson J, Strober M, Suddath R, McCracken JT, Spirito A, Onorato M, Zelazny J, Porta G, Iyengar S, Brent DA. Vitiello B, et al. J Clin Psychiatry. 2019 Oct 23;80(5):19lcx13039. doi: 10.4088/JCP.19lcx13039. J Clin Psychiatry. 2019. PMID: 31556973

Abstract

Background: We examined the long-term outcome of participants in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study, a randomized trial of 334 adolescents (aged 12-18 years) with DSM-IV-defined major depressive disorder initially resistant to selective serotonin reuptake inhibitor (SSRI) treatment who were subsequently treated for 12 weeks with another SSRI, venlafaxine, another SSRI + cognitive-behavioral therapy (CBT), or venlafaxine + CBT. Responders then continued with the same treatment through week 24, while nonresponders were given open treatment.

Method: For the current study, patients were reassessed 48 (n = 116) and 72 (n = 130) weeks from intake. Data were gathered from February 2001 to February 2007. Standardized diagnostic interviews and measures of depression, suicidal ideation, related psychopathology, and level of functioning were periodically administered. Remission was defined as ≥ 3 weeks with ≤ 1 clinically significant symptom and no associated functional impairment (score of 1 on the adolescent version of the Longitudinal Interval Follow-Up Evaluation [A-LIFE]), and relapse, as ≥ 2 weeks with probable or definite depressive disorder (score of 3 or 4 on the A-LIFE). Mixed-effects regression models were applied to estimate remission, relapse, and functional recovery.

Results: By 72 weeks, an estimated 61.1% of the randomized youths had reached remission. Randomly assigned treatment (first 12 weeks) did not influence remission rate or time to remission, but the group assigned to SSRIs had a more rapid decline in self-reported depressive symptoms and suicidal ideation than those assigned to venlafaxine (P < .03). Participants with more severe depression, greater dysfunction, and alcohol or drug use at baseline were less likely to remit. The depressive symptom trajectory of the remitters diverged from that of nonremitters by the first 6 weeks of treatment (P < .001). Of the 130 participants in remission at week 24, 25.4% relapsed in the subsequent year.

Conclusions: While most adolescents achieved remission, more than one-third did not, and one-fourth of remitted patients experienced a relapse. More effective interventions are needed for patients who do not show robust improvement early in treatment.

Trial registration: clinicaltrials.gov Identifier: NCT00018902.

PubMed Disclaimer

Figures

Figure 1
Figure 1
I – Residual Symptoms at Week 72 Assessment – Overall Samplea aPercentage of participants assessed at 72 weeks (N=173) endorsing (score of 3 or above) specific symptoms of the Children's Depression Rating Scale-Revised (CDRS-R). II - Residual Symptoms at Week 72 Assessment – Remitters and Non-Remittersb bPercentage of participants assessed at 72 weeks who had reached remission (N=138) or not (N=35) in TORDIA, endorsing (score of 3 or above) specific symptoms of the Children's Depression Rating Scale-Revised (CDRS-R). Remission is defined as at least three consecutive weeks without clinically significant depressive symptoms, corresponding to a score of 1 on the A-LIFE.
Figure 1
Figure 1
I – Residual Symptoms at Week 72 Assessment – Overall Samplea aPercentage of participants assessed at 72 weeks (N=173) endorsing (score of 3 or above) specific symptoms of the Children's Depression Rating Scale-Revised (CDRS-R). II - Residual Symptoms at Week 72 Assessment – Remitters and Non-Remittersb bPercentage of participants assessed at 72 weeks who had reached remission (N=138) or not (N=35) in TORDIA, endorsing (score of 3 or above) specific symptoms of the Children's Depression Rating Scale-Revised (CDRS-R). Remission is defined as at least three consecutive weeks without clinically significant depressive symptoms, corresponding to a score of 1 on the A-LIFE.
Figure 2
Figure 2
Trajectories of CDRS (left) and in CGAS (right) (estimated means)
Figure 3
Figure 3
Trajectories of Depression Symptoms (CDRS-R) by Remission Status at Week 72
Figure 4
Figure 4
Suicidal Ideation Questionnaire-Adolescent Version (SIQ-Jr) (estimated means)
See this image and copyright information in PMC

Comment in

References

    1. Kennard B, Silva SG, Tonev S, Rohde P, Hughes JL, Vitiello B, Kratochvil CJ, Curry JF, Emslie GJ, Reinecke M, March J. Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry. 2009;48:186–195. - PMC - PubMed
    1. TADS Team The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry. 2009;166:1141–1149. - PubMed
    1. Brent D, Emslie G, Clarke G, Wagner K, Asarnow J, Keller M, Vitiello B, Ritz L, Satish Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Porta G, Onorato M, Zelazny J. The Treatment of Adolescents with SSRI-Resistant Depression (TORDIA). A comparison of switch to venlafaxine or to another SSRI, with or without additional cognitive behavioral therapy. JAMA. 2008;299:901–13. - PMC - PubMed
    1. Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, Iyengar S, Shamseddeen W, Ritz L, Birmaher B, Ryan N, Kennard B, Mayes T, Debar L, McCracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M, Brent D. Treatment of Selective Serotonin Reuptake Inhibitor-Resistant-Depression in Adolescents: predictors and moderators of Treatment Response. J Am Acad Child Adolesc Psychiatry. 2009;48:330–339. - PMC - PubMed
    1. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB. Predictors of spontaneous and systematically assessed suicidal adverse events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry. 2009;166:418–426. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data